Galderma S.A. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
33 Pages - GMD12098
$1,500.00

Summary

Global Markets Direct’s, ‘Galderma S.A. - Product Pipeline Review - 2014’, provides an overview of the Galderma S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galderma S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Galderma S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Galderma S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Galderma S.A.’s pipeline products

Reasons to buy

- Evaluate Galderma S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Galderma S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Galderma S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Galderma S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galderma S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Galderma S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Galderma S.A. Snapshot 5
Galderma S.A. Overview 5
Key Information 5
Key Facts 5
Galderma S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Galderma S.A. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Galderma S.A. - Pipeline Products Glance 13
Galderma S.A. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Galderma S.A. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Galderma S.A. - Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
Galderma S.A. - Drug Profiles 17
(adapalene + benzoyl peroxide) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ivermectin 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CD-07387 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CD-5789 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CD2475/101 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
resiquimod 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Galderma S.A. - Pipeline Analysis 23
Galderma S.A. - Pipeline Products by Target 23
Galderma S.A. - Pipeline Products by Route of Administration 24
Galderma S.A. - Pipeline Products by Molecule Type 25
Galderma S.A. - Pipeline Products by Mechanism of Action 26
Galderma S.A. - Recent Pipeline Updates 27
Galderma S.A. - Dormant Projects 28
Galderma S.A. - Company Statement 29
Galderma S.A. - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Galderma S.A., Key Information 5
Galderma S.A., Key Facts 5
Galderma S.A. - Pipeline by Indication, 2014 7
Galderma S.A. - Pipeline by Stage of Development, 2014 8
Galderma S.A. - Monotherapy Products in Pipeline, 2014 9
Galderma S.A. - Combination Treatment Modalities in Pipeline, 2014 10
Galderma S.A. - Partnered Products in Pipeline, 2014 11
Galderma S.A. - Partnered Products/ Combination Treatment Modalities, 2014 12
Galderma S.A. - Phase III, 2014 13
Galderma S.A. - Phase II, 2014 14
Galderma S.A. - Phase I, 2014 15
Galderma S.A. - Unknown, 2014 16
Galderma S.A. - Pipeline by Target, 2014 23
Galderma S.A. - Pipeline by Route of Administration, 2014 24
Galderma S.A. - Pipeline by Molecule Type, 2014 25
Galderma S.A. - Pipeline Products by Mechanism of Action, 2014 26
Galderma S.A. - Recent Pipeline Updates, 2014 27
Galderma S.A. - Dormant Developmental Projects,2014 28
Galderma S.A., Other Locations 30
Galderma S.A., Subsidiaries 31

List of Figures
Galderma S.A. - Pipeline by Top 10 Indication, 2014 7
Galderma S.A. - Pipeline by Stage of Development, 2014 8
Galderma S.A. - Monotherapy Products in Pipeline, 2014 9
Galderma S.A. - Partnered Products in Pipeline, 2014 11
Galderma S.A. - Pipeline by Top 10 Target, 2014 23
Galderma S.A. - Pipeline by Top 10 Route of Administration, 2014 24
Galderma S.A. - Pipeline by Top 10 Molecule Type, 2014 25
Galderma S.A. - Pipeline Products by Top 10 Mechanism of Action, 2014 26

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax